Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 13/20 | 0.39 |
| ▸ | CDK8 | P49336 | 13/20 | 0.39 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | WNT1 | P04628 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580528 | 0.86 | CCNC (0.44) | CCNCCDK8PIM1 | |
| SCHEMBL4581027 | 0.84 | CCNC (0.44) | CCNCCDK8PRKCZPIM1KDR | |
| SCHEMBL4581989 | 0.79 | POLB (0.36) | CCNCCDK8PIM1 | |
| SCHEMBL4580301 | 0.75 | CCNC (0.56) | CCNCCDK8PRKCZPIM1 | |
| SCHEMBL4578993 | 0.74 | CCNC (0.54) | CCNCCDK8PRKCZ | |
| SCHEMBL5147070 | 0.74 | HTT (0.53) | — | |
| SCHEMBL4581018 | 0.71 | CYP1A2 (0.48) | CCNCCDK8 | |
| SCHEMBL5267766 | 0.71 | CCNC (0.61) | CCNCCDK8PIM1 | |
| SCHEMBL4580344 | 0.71 | CCNC (0.50) | CCNCCDK8PRKCZKDR | |
| SCHEMBL15741796 | 0.71 | HPGD (0.44) | CCNCCDK8DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | claimed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | claimed |
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | SERENEX, INC. | 2006-02-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | CCNA1, FOXM1, CCNA2 | CCNC 289/4885CDK8 516/4885PRKCZ 3718/4885 |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | CCNA1, FOXM1, CCNA2 | CCNC 289/4885CDK8 516/4885PRKCZ 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.